Ixazomib Typical Properties
Item
Specification
Specific rotation
+39.5 to +41.5°
State of solution(transmittance)
Clear 98.0% min.
Chloride[cl]
0.020% max.
Ammonium [NH4]
0.02% max.
Sulfate[SO4]
0.020% max
Iron[Fe]
10ppm max.
Heavy metals [Pb]
10ppm max
Arsenic[As2O3]
1ppm max
Other amino acids
Chromatographically not detectable
Loss on drying
0.20% max.
Residue on ignition[sulfated]
0.10% max.
Assay
99.0% min
Ixazomib product description
MLN2238 is a reversible inhibitor of the β5 site of chymotrypsin-like proteolysis of the 20S proteasome (IC 50 = 3.4 nM in the cell-free assay; K i = 0.93 nM).
It inhibits caspase-like β1 and trypsin-like β2 proteolytic sites with IC 50 values of 0.03 and 3.5 µM, respectively.
MLN2238 is the biologically active form of the prodrug MLN9708. It has shown anti-tumor activity in both cell-based tests and xenograft models, and has been tested for potential anti-myeloma activity in phase III clinical trials.
Ixazomib Usage
Applying for curing multiple myelomaand some form of leukemia and C19
Ixazomib Packaging and Shipping
Packaging:1 g/package , as customer’s request
Shipping:It can be according to the customer’s request
Ixazomib storage
Room temperature
Ixazomib function
Ixazomib is a reversible protein body inhibitor. Ixazomib preferentially binds to and inhibits the activity of the β5 subunit of the chymotrypsin-like 20S proteasome.
Ixazomib induces apoptosis of multiple myeloma cell lines in vitro.
Ixazomib shows in vitro cytotoxicity on myeloma cells from patients who have relapsed after a variety of previous treatments, including bortezomib, lenalidomide, and dexamethasone.
The combination of Ixazomib and lenalidomide showed a synergistic cytotoxic effect in multiple myeloma cell lines.
In vivo, ixazomib showed anti-tumor activity in a murine multiple myeloma tumor xenograft model.
